JSPR Key Statistics, Chart & Performance
The current stock price of JSPR is 1.91 USD. In the past month the price increased by 12.35%. In the past year, price decreased by -91.42%.
JSPR Latest News, Press Relases and Analysis
JSPR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.12 | 402.80B | ||
| AMGN | AMGEN INC | 15.15 | 178.45B | ||
| GILD | GILEAD SCIENCES INC | 15.16 | 154.04B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.52 | 116.79B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.32 | 81.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 799.47 | 53.87B | ||
| INSM | INSMED INC | N/A | 37.48B | ||
| NTRA | NATERA INC | N/A | 32.51B | ||
| BIIB | BIOGEN INC | 10.44 | 25.63B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.47 | 22.12B | ||
| INCY | INCYTE CORP | 15.69 | 19.77B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.32B |
Related stock screener links
About JSPR
Company Profile
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. The company is headquartered in Redwood City, California and currently employs 64 full-time employees. The company went IPO on 2019-11-20. The firm is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. The firm's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. The SCF/c-Kit pathway is a survival signal for mast cells. The company is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.
Company Info
JASPER THERAPEUTICS INC
2200 Bridge Pkwy Suite #102
Redwood City CALIFORNIA US
CEO: Bala Venkataraman
Employees: 64
Phone: 16505491400
JASPER THERAPEUTICS INC / JSPR FAQ
What does JASPER THERAPEUTICS INC do?
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. The company is headquartered in Redwood City, California and currently employs 64 full-time employees. The company went IPO on 2019-11-20. The firm is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. The firm's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. The SCF/c-Kit pathway is a survival signal for mast cells. The company is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.
What is the current price of JSPR stock?
The current stock price of JSPR is 1.91 USD. The price increased by 2.69% in the last trading session.
Does JSPR stock pay dividends?
JSPR does not pay a dividend.
What is the ChartMill rating of JASPER THERAPEUTICS INC stock?
JSPR has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the market capitalization of JSPR stock?
JASPER THERAPEUTICS INC (JSPR) has a market capitalization of 53.44M USD. This makes JSPR a Micro Cap stock.
JSPR Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to JSPR. When comparing the yearly performance of all stocks, JSPR is a bad performer in the overall market: 96.17% of all stocks are doing better.
JSPR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to JSPR. The financial health of JSPR is average, but there are quite some concerns on its profitability.
JSPR Financial Highlights
Over the last trailing twelve months JSPR reported a non-GAAP Earnings per Share(EPS) of -6.02. The EPS decreased by -27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -158.38% | ||
| ROE | -786.63% | ||
| Debt/Equity | 0 |
JSPR Forecast & Estimates
14 analysts have analysed JSPR and the average price target is 12.92 USD. This implies a price increase of 576.44% is expected in the next year compared to the current price of 1.91.